When markets soar, fear sets in. But ditching a regular investing strategy at the top could sabotage long-term success.

Elston’s Bruce Williams discuss ResMed's results and margin momentum, and whether the stock still deserves a buy rating.

Not sure where to start this ASX FY25 reporting season? NAOS analyses keywords in earnings call transcripts to reveal the ...